Positive results of a study into the effects of an add-on to antipsychotics for the management of treatment-resistant schizophrenia (TRS) have been announced by Newron Pharmaceuticals.
The AstraZeneca-owned company Alexion has teamed up with Verge Genomics to deploy the U.S. startup’s drug discovery platform in the search for novel drug targets for rare neurodegenerative and neuromuscular diseases.
Less than a month after the U.S. Food and Drug Administration (FDA) gave its antidepressant drug zuranolone (Zurzuvae) a mixed welcome, Sage Therapeutics has launched plans to reorganize its operations by refocusing its drug development efforts and laying...
Drugs like Annovis Bio’s buntanetap and prasinezumab have the potential to “revolutionize the treatment of Parkinson’s Disease” says analytics company, GlobalData, an analytics company, but it is a complex road ahead.
Sygnature Discovery has launched an in vivo inflammation model, that the company says is ‘exciting but only the beginning’ of understanding life-limiting neuroinflammatory conditions.
H1, a US data healthcare data technology company has been selected by non-profit funder of Parkinson’s Disease (PD) research, The Michael J Fox Foundation (MJFF), for its Trial Landscape solution.
Cumulus Neuroscience has been given the clearance by the US Food and Drug Administration (FDA) and the company says this will accelerate treatments for neuropsychiatric and neurodegenerative disorders.
The National Institute for Health and Care Excellence is weighing the viability of PD Neurotechnology’s PDMonitor system for Parkinson’s disease patients.
The agency has approved an expanded indication for Qelbree extended-release capsules to treat attention deficit hyperactivity disorder in younger patients.
The company’s Precision Olfactory Delivery technology, currently combined with its Trudhesa migraine treatment, reportedly facilitates high absorption rates.
The CDMO has been awarded funding from the US government to work on treatments for sarin and other substances used frequently employed in chemical attacks.
The biomarker developer is partnering with Alzheimer Center Amsterdam on decentralized assessment of patient cognition and function in preclinical research.
The drug has received the agency’s seal of approval to treat seizures associated with difficult-to-treat seizures associated with Lennox-Gastaut syndrome.
The US- and Hungary-based pharma firms will work on research, development, and commercialization of dopamine receptor modulators for potential treatments.
The AI-centered genomics company is joining with Don’t Forget Morgan, a group for patients with BPAN, to explore treatments for the neurodegenerative condition.
The institute and the research/support organization will collaborate on development of novel therapies aimed at treating the central nervous system disorder.
The decentralized tech specialist has acquired Digital Artefacts, a research tech firm focused on cognitive, behavioral, and physiological data capture.
Three organizations have merged to form Apex Innovative Sciences, an independent clinical trial site operator focused on Phase I-IV studies for central nervous system indications and other therapeutic areas, including neurology, psychiatry, addiction,...
Sponsors to benefit from more accurate, shorter, and less costly trials through Shimmer Research and ClearSky Medical Diagnostics partnerships, says company executive.
AbbVie is collaborating with MC10 to use its wearable system to gather insights on possible metrics and digital biomarkers that can be applied to MS trials.
Lundbeck extends its research collaboration with the drug discovery services provider Enamine to help “intensify its search for quality lead compounds.”
Lonza and Emerald Health enter an agreement for the large-scale manufacturing of a synthetic derivative of CBD and its oral drug product for the treatment of MS and other CNS diseases.
PinneyAssociates and NMS Labs will plan, conduct, and analyze in vitro laboratory testing of pharmaceutical formulations to evaluate any abuse-deterrent properties, says CMO.
Clinigen’s newly announced business, Clinical Trial Service, will establish an on-demand supply chain for clinical trials and extends agreement with its partner Accord.
For research in areas such as Parkinson’s disease, digital endpoints may soon be used as primary endpoints, allowing for in-home clinical trials to be conducted over longer periods of time, says CRO.